XCELLIT
LIVE

Serial Number

97664402

Owner

LAKEFRONT BIOTHERAPEUTICS NV

Attorney

Alexandra MacKay

Filing Date

Nov 5, 2022

Add to watchlist:

No watchlists yet
View on USPTO

XCELLIT Trademark

Serial Number: 97664402 • Registration: 7313858

XCELLIT is a trademark filed by LAKEFRONT BIOTHERAPEUTICS NV on November 5, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

LAKEFRONT BIOTHERAPEUTICS NV

SCHALIËNHOEVEDREEF 20 BOX T
MECHELEN 2800 , BE

Entity Type: 03

Galapagos NV (19 trademarks)

Mechelen B-2800 , BE

Entity Type: 03

Trademark Details

Filing Date

November 5, 2022

Registration Date

February 27, 2024

Published for Opposition

December 12, 2023

Goods & Services

Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment

Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 26, 2026 ASGN
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 27, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 27, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 6, 2023 CNSA
ASSIGNED TO EXAMINER
Nov 6, 2023 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 18, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 18, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 17, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 24, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 24, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 24, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 21, 2023 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 19, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 19, 2023 CRFA
ASSIGNED TO LIE
Jan 19, 2023 ALIE
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 23, 2022 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 19, 2022 PARI
NEW APPLICATION ENTERED
Nov 9, 2022 NWAP